1. Home
  2. KALV vs UVE Comparison

KALV vs UVE Comparison

Compare KALV & UVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.68

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo UNIVERSAL INSURANCE HOLDINGS INC

UVE

UNIVERSAL INSURANCE HOLDINGS INC

HOLD

Current Price

$39.00

Market Cap

957.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
UVE
Founded
N/A
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
957.6M
IPO Year
2014
1996

Fundamental Metrics

Financial Performance
Metric
KALV
UVE
Price
$26.68
$39.00
Analyst Decision
Strong Buy
Buy
Analyst Count
5
1
Target Price
$32.60
$40.00
AVG Volume (30 Days)
2.7M
180.3K
Earning Date
07-09-2026
04-23-2026
Dividend Yield
N/A
1.97%
EPS Growth
N/A
214.43
EPS
N/A
1.88
Revenue
$50,000,000.00
$1,603,915,000.00
Revenue This Year
$185.42
N/A
Revenue Next Year
$59.23
$2.88
P/E Ratio
N/A
$20.91
Revenue Growth
495.66
5.48
52 Week Low
$9.83
$21.96
52 Week High
$26.76
$41.96

Technical Indicators

Market Signals
Indicator
KALV
UVE
Relative Strength Index (RSI) 75.31 63.81
Support Level $14.43 $30.96
Resistance Level N/A N/A
Average True Range (ATR) 0.97 1.52
MACD 0.53 0.52
Stochastic Oscillator 99.01 68.13

Price Performance

Historical Comparison
KALV
UVE

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About UVE UNIVERSAL INSURANCE HOLDINGS INC

Universal Insurance Holdings Inc is an insurance holding company. Through its subsidiaries, the company mainly offers property and casualty insurance and value-added insurance services. It develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners lines of business and performs all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The group offers the following types of personal residential insurance: homeowners, renters/tenants, condo unit owners, and dwelling/fire, through an independent agent network and online distribution channels across multiple states in the United States of America.

Share on Social Networks: